We found that CD31 expression in tumor tissues (Figure 4H) and TDLNs was lower in the bevacizumab group than in the control group (Figure 4I), suggesting that VEGFA promoted angiogenesis in TDLNs. Here, PECAM1 is linked to neoplasm.